We expect the upcoming prelims to show another year of solid growth. UDG continues to benefit from structural growth in its markets and deploys its firepower on margin enhancing acquisitions. We upgrade FY18/19 EPS forecasts by 7% to reflect the MicroMass deal, but leave FY17 unchanged. We expect further acquisition-led upgrades in due course, potentially of 40-50%. This underpins the medium term investment case and should support the rating, which on normal conventions looks full. We stay at H ....
01 Nov 2017
N+1 Singer - UDG Healthcare - Further upgrades underpin investment thesis
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - UDG Healthcare - Further upgrades underpin investment thesis
- Published:
01 Nov 2017 -
Author:
Chris Glasper -
Pages:
5
We expect the upcoming prelims to show another year of solid growth. UDG continues to benefit from structural growth in its markets and deploys its firepower on margin enhancing acquisitions. We upgrade FY18/19 EPS forecasts by 7% to reflect the MicroMass deal, but leave FY17 unchanged. We expect further acquisition-led upgrades in due course, potentially of 40-50%. This underpins the medium term investment case and should support the rating, which on normal conventions looks full. We stay at H ....